Cancer biopsy market seen reaching $53.38 billion by 2030

The cancer biopsy market is projected to grow from $32.41 billion in 2026 to $53.38 billion by 2030, driven by rising cancer cases, wider use of liquid biopsy and stronger demand for precision oncology diagnostics. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Cancer biopsy is a core diagnostic tool for confirming cancer and guiding treatment decisions. - The market is expanding as health systems push earlier detection, more precise diagnosis and less invasive testing. - Rising global cancer incidence is increasing demand for biopsy services, devices and lab infrastructure.

What happened: - The Business Research Company published its Cancer Biopsy Market Report 2026, covering market size, trends and global forecasts through 2035. - The report estimates the cancer biopsy market will grow from $28.52 billion in 2025 to $32.41 billion in 2026. - The report projects the market will reach $53.38 billion by 2030, implying a 13.3% CAGR over the forecast period. - A free sample of the report is available here. - The full report is available here.

The details: - The market’s recent growth was supported by rising global cancer incidence, broader access to diagnostic imaging and wider use of tissue biopsy as a diagnostic standard. - Growth also reflected expansion of pathology laboratory networks and advances in biopsy device technology. - Future growth drivers include precision oncology diagnostics, liquid biopsy adoption, personalized cancer treatment strategies, molecular diagnostics investment and stronger emphasis on early cancer screening. - Expected trends include wider use of liquid biopsy, more image-guided biopsy procedures, integration of molecular pathology testing, development of minimally invasive biopsy devices and a greater focus on early-stage cancer detection. - A cancer biopsy involves extracting a small tissue or cell sample from a suspicious area and analyzing it to confirm cancer or another condition. - Imaging tools such as CT scans and MRIs can show abnormalities, but biopsy can provide a definitive diagnosis. - The report says biopsies are essential for cancer detection and treatment planning. - The report identifies North America as the largest regional market in 2025. - The report expects Asia-Pacific to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The forecast points to a market that is shifting from basic confirmation testing toward more targeted and less invasive diagnostics. - The emphasis on liquid biopsy and molecular pathology suggests growing demand for tests that can support personalized treatment decisions. - The WHO projected in February 2024 that more than 35 million new cancer cases could be diagnosed globally by 2050, up 77% from about 20 million cases in 2022. - That outlook helps explain why diagnostic capacity remains a priority for both mature and emerging healthcare markets.

What's next: - Market growth will likely track adoption of liquid biopsy, image-guided procedures and molecular diagnostics. - Early screening programs and investment in precision oncology are expected to remain central demand drivers. - Regional growth momentum is likely to stay strongest in Asia-Pacific as healthcare infrastructure and diagnostic access expand. - The Business Research Company says the 2026 report also adds market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics and updated trend analysis.

The bottom line: - Cancer biopsy remains a foundational cancer diagnostic market, and the next leg of growth is being shaped by earlier detection, more precise testing and less invasive technologies.